GM1 Gangliosidosis Market Report 2026

The gm1 gangliosidosis market size has grown rapidly in recent years. It will grow from $0.57 billion in 2025 to $0.63 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rare disease research initiatives, enzyme deficiency identification, advances in genetic diagnostics, hospital-based pediatric care, early clinical studies.

The gm1 gangliosidosis market size is expected to see rapid growth in the next few years. It will grow to $0.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to gene therapy pipeline growth, orphan drug incentives, improved diagnostic screening, increased patient advocacy, biotechnology funding expansion. Major trends in the forecast period include rising focus on rare disease drug development, increased research in gene therapy, growing use of enzyme replacement therapies, expansion of newborn genetic screening, increased clinical trial activity.

The increasing adoption of gene therapy is expected to drive the growth of the GM1 gangliosidosis market in the coming years. Gene therapy involves modifying or replacing genes within a patient’s cells to treat or prevent disease. Its growing adoption is fueled by advancements in genetic research, improved outcomes for previously untreatable conditions, and stronger regulatory support for innovative therapies. In GM1 gangliosidosis, gene therapy delivers a functional copy of the defective GLB1 gene to patient cells, restoring β-galactosidase enzyme activity and reducing toxic substrate accumulation. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization, reported that in Q4 2023, the number of gene therapies in Phase III increased by 10% compared to the previous quarter, marking the first rise since Q3 2022. Therefore, the increasing adoption of gene therapy is driving growth in the GM1 gangliosidosis market.

Major companies in the GM1 gangliosidosis market are focusing on strategic partnerships to maintain and strengthen their market position. Such partnerships are vital for advancing gene therapy development, as they combine expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For instance, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, partnered with the Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement includes up to $100 million in funding from Fiocruz for clinical research and manufacturing, with the goal of making these advanced therapies accessible through Brazil’s public healthcare system. This collaboration emphasizes technology transfer and aims to expand access to treatments previously limited to higher-income populations.

In August 2024, Passage Bio Inc., a US-based biotech company, partnered with GEMMA Biotherapeutics to advance pediatric gene therapies. Under this collaboration, Passage Bio is out-licensing three pediatric gene therapies targeting lysosomal storage disorders, including PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy. GEMMA Biotherapeutics Inc. is a US-based biotechnology company specializing in the development and commercialization of genetic medicines for rare pediatric diseases.

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc.

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gm1 gangliosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the GM1 gangliosidosis market by increasing costs of imported biologics, diagnostic kits, and gene therapy components. Research institutes and hospitals are most affected due to reliance on imported advanced therapies. These tariffs increase treatment costs by raising expenses for ultra-rare disease diagnostics, investigational gene therapies, and long-term supportive care, limiting patient access and slowing clinical research progress. However, they support domestic biopharmaceutical manufacturing, encouraging local development of biologics, gene therapy platforms, and rare disease treatment infrastructure.

The gm1 gangliosidosis market research report is one of a series of new reports that provides gm1 gangliosidosis market statistics, including gm1 gangliosidosis industry global market size, regional shares, competitors with a gm1 gangliosidosis market share, detailed gm1 gangliosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the gm1 gangliosidosis industry. This gm1 gangliosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

GM1 gangliosidosis is a rare inherited neurodegenerative disorder caused by a deficiency of the β-galactosidase (GLB1) enzyme, leading to the toxic buildup of GM1 gangliosides in the brain and other tissues. The condition results in progressive neurological deterioration, developmental delays, muscle weakness, and enlargement of organs.

The main types of GM1 gangliosidosis are type 1 GM1 gangliosidosis, type 2 GM1 gangliosidosis, and type 3 GM1 gangliosidosis. Type 1 GM1 gangliosidosis is the most severe form, typically diagnosed in infancy, and is marked by rapid neurological decline. Affected children experience progressive motor and cognitive deterioration, often leading to early death. Treatment options include anticonvulsants, bone marrow transplantation, cord-blood hematopoietic stem cell transplantation, enzyme replacement therapy, and gene therapy. These therapies are utilized by research institutes, hospitals, and other healthcare facilities.

The GM1 gangliosidosis market consists of revenues earned by entities by providing services such as gene therapy, diagnostic testing, patient care, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The GM1 gangliosidosis market also includes sales of diagnostic tools, research kits, biomarkers, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.